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Abstract 22 
This study characterised in vitro potencies of anti-leishmanial agents against intracellular 23 
Leishmania donovani amastigotes in primary human macrophages, obtained with or without 24 
CD14-positive monocyte enrichment, phorbol 12-myristate 13-acetate (PMA) differentiated 25 
THP-1 cells and mouse peritoneal exudate macrophages (PEMs). Host cell dependent 26 
potency was confirmed for pentavalent and trivalent antimony. Fexinidazole was inactive 27 
against intracellular amastigotes across the host cell panel. Fexinidazole sulfone, (R)-PA-824, 28 
(S)-PA-824 and VL-2098 displayed similar potency in all host cells tested.  29 
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Parasites of the genus Leishmania are causative agents of Neglected Tropical Diseases 48 
(NTDs) known as the leishmaniases. In the host, parasites survive and multiply as 49 
intracellular amastigotes in the parasitophorous vacuole of primarily tissue-resident 50 
macrophages (1). Main disease manifestations include visceral leishmaniasis (VL) (2) and 51 
cutaneous leishmaniasis (CL) (3). VL is caused by infection with L. donovani or L. infantum 52 
(2) and estimated to cause more than 50 000 deaths per year (4). Limitations of current 53 
chemotherapeutics include the need for long treatment courses, variable treatment responses 54 
between endemic regions, safety concerns and lack of drug stability in hot climates (5, 6). 55 
With increased support for drug research and development for NTDs the last decade has seen 56 
increased efforts in drug discovery for leishmaniasis. This was accompanied by the set-up of 57 
high-throughput, high-content platforms to screen compounds against intracellular 58 
Leishmania amastigotes in mammalian host cells (7-9). Different mammalian cells are used 59 
for this purpose. However, host cell properties are amongst the determinants of directly 60 
acting drugs, which need to accumulate in infected host cells to exert their anti-leishmanial 61 
effects, and immunomodulatory agents, which affect cellular pathways to kill intracellular 62 
parasites indirectly. Involvement of host cell transporters has been demonstrated in drug 63 
accumulation and treatment outcome for antimonials (10, 11) and miltefosine (12). The 64 
nature of the host cell has been shown to impact on the in vitro potency of the standard anti-65 
leishmanial drug sodium stibogluconate (SSG) (13). Hence, the current study was undertaken 66 
to characterise potencies of current lead compounds and drug candidates against intracellular 67 
L. donovani amastigotes in a panel of different host cells.    68 
Selection of host cells was focussed on human derived cells to ensure relevance to 69 
clinical use. Peritoneal exudate mouse macrophages (PEMs) were included as they have an 70 
established role in anti-leishmanial drug evaluations. Compounds profiled included the 71 
nitroheterocyclic drugs fexinidazole and its sulfone metabolite (14), VL-2098 (15) and the 72 
(R) and (S) enantiomers of PA-824 (16). Notably fexinidazole has entered clinical trials for 73 
VL (www.dndi.org). Since SSG (pentavalent antimony) is a pro-drug and requires conversion 74 
to the trivalent form (17), we included both oxidation states in the current study.  75 
THP-1 cells (ATCC-TIB-202, LGC Ltd., Teddington, UK), PEMs, harvested from 76 
BALB/c or CD-1 mice (LSHTM breeding colony), and human peripheral blood mononuclear 77 
cells (PBMCs), harvested from heparinised blood collected from adult human donors, were 78 
prepared as described (13). Autologous plasma was centrifuged for 30 minutes at 2,000 x g at 79 
20°C and stored at 4°C for the duration of the experiment. Mononuclear cells were re-80 
suspended in RPMI 1640 medium plus penicillin (100 U/ml), streptomycin (100 μg/ml) and 81 
10% autologous plasma and differentiated at 37°C, 5% CO2 for a total of 6 days with addition 82 
of fresh medium after 3 days. Selected assays used monocytes obtained through positive 83 
immunomagnetic selection with CD14 MicroBeads (MACS; Miltenyi Biotec), following the 84 
manufacterer’s protocol. The CD14-positive monocyte-enriched fraction was re-suspended in 85 
RPMI 1640 medium plus 10% hi-FBS, 100 ng/ml recombinant human M-CSF (R&D 86 
Systems, UK) and penicillin (100 U/mL) / streptomycin (100 mg/mL) and differentiated at 87 
37°C, 5% CO2 for 6 days. Prior to infection cells were washed with fresh medium containing 88 
no antibiotic. Depending on the final number of cells obtained, PBMC derived macrophages 89 
from 2-3 individual donors were either combined or plated separately for drug potency 90 
evaluations. At the time of drug addition cells obtained without CD14 selection were > 85% 91 
macrophages as estimated by morphological appearance in Giemsa-stained preparations and 92 
those obtained with positive CD14 selection 100%. Host cells, plated in Lab-tek 16-well 93 
chamber slides (Fisher Scientific, UK) at a density of 4 x 104 cells/well, were infected with 94 
Leishmania donovani (MHOM/ET/67/HU3) amastigotes, harvested from Rag-1-knockout 95 
(B6) mice (LSHTM breeding colony), as described (13). Infected cultures were exposed to 6 96 
point (4 point when limited by cell number) serial compound dilutions (2-fold, 3-fold for 97 
antimonials) or assay medium (untreated controls) for 3 days (no medium change) or 5 days 98 
(medium change after 3 days). Each concentration and control was tested in quadruplicate. 99 
Upon termination of the assay slides were prepared and data evaluated as described (13). 100 
Percentage of infected cells was used to estimate EC50 and EC90 values as the clinically most 101 
relevant read out. Intracellular burden in untreated controls was determined by counting the 102 
number of amastigotes in 50 infected host cells per well. Experiments were carried out in a 103 
direct comparative assay design in which different host cell types were infected at the same 104 
time with the same batch of parasites and exposed to dilutions prepared from the same stock 105 
solution of compounds. This approach was chosen to ensure that any variation in drug 106 
potency between different cell types could be attributed to cell type rather than day-to-day 107 
differences in parasite or drug preparation. Structurally related compounds were tested in 108 
parallel in the same experiment and miltefosine (Zentaris GmbH, Germany) included as 109 
standard drug in selected assays. Nitroheterocyclic drugs were synthesised at the University 110 
of Dundee as described (14, 16). VL-2098 was prepared in a single step from 4-111 
(trifluoromethoxy)phenol and (R)-2-bromo-1-((2-methyloxiran-2-yl)methyl)-4-nitro-1H-112 
imidazole using a modification of the published synthesis of delamanid (OPC-67683) (18). 113 
Potassium antimonyl tartrate trihydrate (trivalent antimony) was obtained from Sigma, UK 114 
and SSG from GSK, UK. Aqueous stock solutions of SSG, potassium antimonyl tartrate 115 
trihydrate and miltefosine were prepared as described previously (13), those of other 116 
compounds in dimethylsulfoxide (Sigma, UK).  117 
Experiments involving animals were approved by the Animal Welfare and Ethics 118 
Review Board at LSHTM and performed under license in accordance with the Animals 119 
(Scientific Procedures) Act 1986 (UK Home Office Project Licence PPL70/6997). For blood 120 
donations consenting volunteers were recruited through an anonymous blood donation 121 
system. Approval for blood donations and the specific study was given by the LSHTM Ethics 122 
Committee (reference numbers 5520 and 6404).  123 
At the EC50 level both pentavalent and trivalent antimony were more potent against L. 124 
donovani amastigotes in primary human macrophages compared to differentiated THP-1 125 
cells, by factors of 21 to >100. The difference in SSG’s potency between these two cell types 126 
is consistent with previous observations (13). As different methodologies exist for the 127 
generation of primary human macrophages (10, 13, 19) and cells obtained from total PBMC 128 
fractions by plastic adherence may contain lymphocyte and platelet contaminations (20) we 129 
wanted to rule out that the methodology used affected our conclusion. Hence we additionally 130 
evaluated SSG’s potency in macrophages generated from CD-14 positive enriched 131 
monocytes. Again SSG was more potent in primary human macrophages compared to 132 
differentiated THP-1 cells tested in parallel, with up to 20 fold differences at the EC50 level. 133 
Also, SSG displayed anti-leishmanial activity in primary human macrophages already after 3 134 
days exposure when either isolation method was used. Data is summarised in Table 1. In 135 
macrophages obtained from CD-14 positive enriched monocytes EC90 values were 136 
consistently higher than those estimated in macrophages obtained from total PBMC fractions. 137 
However, it should be noted that a systematic comparison of SSG’s potency between the two 138 
cell isolation procedures was outside the scope of this study. Since the in vitro potency of 139 
SSG has been shown to decrease with increasing infection levels (21) it is important to note 140 
that infection levels in macrophages obtained from CD-14 positive enriched monocytes or 141 
differentiated THP-1 cells were not higher than those in macrophages obtained from total 142 
PBMC fractions (Supplementary Table 1).   143 
Anti-leishmanial potencies of the nitroheterocyclic compounds (R)-PA-824, (S)-PA-144 
824 and VL-2098 displayed less than 3-fold differences against amastigotes in primary 145 
human macrophages compared to differentiated THP-1 cells at the EC50 and EC90 level after 146 
3 days of compound exposure. Previously reported differences in anti-leishmanial activity 147 
between the two enantiomers of PA-824 (16) were confirmed in both human derived host 148 
cells. Larger variations between assays were observed for fexinidazole sulfone, resulting in 2-149 
10 fold differences at the EC50 level. However, variable quality of dose response curve fits, 150 
as checked visually, was noted between experiments. Fexinidazole was inactive at 151 
concentrations up to 80 µM in both human derived cell types. Data is summarised in Table 2. 152 
Due to the absence of apparent host cell dependent drug action no further investigation was 153 
carried out for nitroheterocyclic compounds in macrophages generated from CD-14 positive 154 
enriched monocytes. Estimation of the steepness of the dose response curves through Hill 155 
slopes gave values of >1 for VL-2098, (R)-PA-824 and (S)-PA-824 and <1 for fexinidazole 156 
sulfone. Levels of infection in human derived host cells were similar and increased over the 157 
course of the experiments, but differed in PEMs (Supplementary Table 21). Hence, potencies 158 
against L. donovani amastigotes in PEMs are reported in Table 2 without direct comparisons 159 
to the human derived cells. Potencies were in agreement with values reported in the literature 160 
(14-16).  161 
Cell lines are often used over primary cells due to ease of culture and an argument of 162 
homogeneity. PMA differentiated THP-1 cells are widely used in anti-leishmanial drug 163 
research, but different stimulation conditions are reported (7, 8, 10, 22). The host cell’s 164 
ability to sustain infection with Leishmania parasites and comparison of potency of reference 165 
compounds to other host cells and assay formats has been the focus in developing protocols 166 
for anti-leishmanial drug evaluation using differentiated THP-1 cells. However it has been 167 
shown that certain cell characteristics, including lysosomal structures, differ when different 168 
stimulus conditions are used (23). Of note, lowering extracellular oxygen tension from 18% 169 
to 5% O2 has also been shown to affect PMA induced THP-1 cell differentiation and function 170 
(24). So far, these effects have not been explored in anti-leishmanial drug research. 171 
Using primary human macrophages derived from individual blood donors we found drug 172 
potencies to be consistent between different donors (Fig. 1), but monocyte isolation requires a 173 
more dedicated approach than standard cell culture and macrophage yields are less 174 
predictable.  175 
In summary, we show that antimonials are a class of compounds where the choice of 176 
host cell affects drug potency under the conditions tested and provide potency profiles of 177 
current anti-leishmanial lead and drug candidates in human derived host cells, including 178 
primary macrophages. Antimonials have been shown to cause oxidative stress and activation 179 
of L. donovani infected host cells in vitro with generation of ROS, NO and TNF-alpha and 180 
subsequent killing of intracellular parasites (25, 26). Drug transporters at the host cell level 181 
have been linked to clinical responses to antimonial treatment and drug resistance (10, 11, 182 
27). Modulation of gene expression profiles by SSG has also been demonstrated in vitro and 183 
increased levels of glutathione were measured in SSG treated compared to untreated host 184 
cells (28). It is possible that differences in the response to oxidative stress, production of 185 
cytokines, expression of drug transporters or a combination of these factors between different 186 
host cells account for the host-cell dependent phenotype of antimonial drug action.  187 
Primary human macrophages emerged as the favourable cell type when investigating 188 
antimonials and are arguably closer to macrophages the parasite will encounter in humans 189 
than differentiated THP-1 cells and PEMs, but all cell types supported similar anti-190 
leishmanial potency of the nitroheterocyclic compounds. To enable evidence based host cell 191 
choice in anti-leishmanial drug research systematic functional characterisation of the different 192 
cell types and their cell-parasite interactions are needed. Finally, the lack of anti-leishmanial 193 
activity of fexinidazole in all three cell types tested underlines the importance of drug 194 
metabolism for successful treatment outcomes with this drug.      195 
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Figure legends 321 
Table 1. Characterisation of cell type dependent potency of antimonials in primary 322 
human macrophages and differentiated THP-1 cells. 323 
Experiment (Expt.) numbers indicate parallel testing of antimonials in assays with the same 324 
number, days indicates the number of days of continuous drug exposure, PBMC derived mФ 325 
refers to macrophages obtained without positive (CD14) selection, PBMC derived mФ 326 
(CD14+) refers to macrophages obtained from positively selected (CD14+) monocytes. EC50 / 327 
90 values are given in µg Sb/mL with 95% confidence intervals in brackets, - not determined. 328 
aCells were derived from two individual blood donors. 329 
bCells were derived from the same blood donor. 330 
c,d,e  Percentage inhibition at 30 µg Sb/ml was 51.6%, 73.3% and 77.8% respectively. 331 
Miltefosine was included as positive control and displayed EC50 / 90 values (95% confidence 332 
intervals in brackets) of 7.97 µM (4.47 – 11.47) / >20 µM in differentiated THP-1 cells and 333 
1.61 µM (1.24 – 1.98) / >5 µM in PBMC derived mФ in expt 1. In expt. 2 respective values 334 
were 1.64 µM (1.35 – 1.93) / 7.77 µM (6.42 – 9.12) and 1.42 µM (1.38 – 1.45) / 3.92 µM 335 
(2.78 – 5.07).  336 
 337 
Table 2. Potency of nitroheterocyclic compounds against intracellular L. donovani 338 
amastigotes in three different host cell types. 339 
Experiment (Expt.) numbers indicate parallel testing of respective compounds in assays with 340 
the same number. EC50 / 90 values are given in µM with 95% confidence intervals in 341 
brackets. Data is representative of 2 - 4 separate directly comparative experiments.  342 
- not determined, N.O. not obtained. 343 
aCells were derived from two individual blood donors.  344 
bPEMs were harvested from CD-1 mice in this assay and BALB/c mice in all other assays.  345 
Miltefosine was included as positive control in expt. 4 and displayed EC50 values (95% 346 
confidence intervals in brackets) of 8.58 µM (6.39 – 10.76) in differentiated THP-1 cells, 347 
2.67 µM (1.78 – 3.57) in PBMC derived mФ and 1.19 µM (0.83-1.54) in PEMs.   348 
  349 
Figure 1. Comparison of EC50 values between primary human macrophages obtained 350 
from different blood donors.  351 
Data is given for 3 day compound exposures to fexinidazole sulfone (A), (R)-PA-824 (B), 352 
(S)-PA-824 (C), VL-2098 (D) and for 5 day exposures to SSG (E). Symbols represent results 353 
with cells from individual blood donors (full circles) or with cells pooled from 2-3 individual 354 
blood donors (full triangles).   355 
  356 
Table 1. 
 
 
 
 
 
 
 
 
 
 Expt. Days  PBMC derived mФ Differentiated THP-1 cells PBMC derived mФ (CD14+) 
   EC50 EC90 EC50 EC90 EC50 EC90 
SbV 1 3 5.39 (4.68-6.11) 10.22 (9.59-10.86) - - - - 
         
SbV 2 5 5.17 (4.62-5.71)a 11.20 (9.48-12.92)a 108.76 (53.52-164.00) >200 - - 
 2 5 2.43 (1.66-3.20)a 10.27 (4.14-16.39)a     
SbIII 2 5 0.10 (0.09-0.11)a >0.17a >10 >10 - - 
 2 5 0.08 (0.07-0.08)a >0.17a     
         
SbV 3 3 - - >900 >900 15.08 (11.70-18.46)b >30b,c 
 3 5 - - 117.62 (84.91-150.34) >900 11.11 (8.58-13.65)a,b >30a,b,d 
 3 5 - -   6.01 (5.59-6.42)a >30a,e 
Table 2.  
 
 
  
  Differentiated THP-1 cells PBMC derived mФ PEMs 
Drug Expt. EC50 EC90 EC50 EC90 EC50 EC90 
(R)-PA-824 1 2.91 (2.77-3.04) 6.56 (4.66-8.47) 4.59 (4.15-5.03)a 5.76 (5.25-6.27)a 1.16 (0.89-1.42) 5.58 (3.25-7.92) 
 1   2.63 (2.37-2.89)a 4.92 (4.36-5.47)a   
 2 4.01 (3.94-4.09) 8.39 (6.93-9.58) 5.06 (4.55-5.57) 7.27 (6.46-8.09) 2.26 (2.09-2.44)b 4.55 (3.46-5.64)b 
        
(S)-PA-824 1 27.83 (24.95-30.71) >40 38.62 (37.53-39.70) >40 13.03 (8.05-18.02) N.O. 
 2 27.90 (25.32-30.49) 50.82 (44.66-26.97) 30.57 (26.73-34.41) 37.82 (35.88-39.77) 13.53 (11.67-15.39)b N.O. 
        
VL-2098 1 0.22 (0.21-0.23) 0.36 (0.32-0.41) 0.32 (0.31-0.34) 0.48 (0.45-0.50) 0.23 (0.20-0.26) 0.45 (0.37-0.54) 
 2 - - 0.39 (0.36-0.42) 0.56 (0.52-0.61) 0.23 (0.21-0.24)b 0.45 (0.35-0.56)b 
 3 - - 0.27 (0.21-0.33) 0.41 (0.39-0.43) - - 
        
Fexinidazole 3 >80 >80 >80a >80 a >80 >80 
 3   >80 a >80 a   
        
Fexinidazole 
sulfone 
1 3.15 (2.06-4.25) >20 7.57 (6.72-8.43)a >40a 5.59 (5.21-5.96) >20 
 1   6.85 (4.56-9.13)a >40a   
 3 8.43 (7.38-9.49) >40 9.37 (4.66-14.07)a >80a 10.44 (6.88-14.00) >40 
 3   14.70 (10.73-18.68)a >80a   
 4 2.24 (1.42-3.06) >80 20.94 (17.02-24.86) >80 10.27 (5.64-14.90) >20 
Figure 1.  
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